A surprising discovery by researchers at Johns Hopkins University has raised hopes for a new approach to treating Parkinson’s disease. Scientists found that blocking a specific interaction between two proteins may prevent harmful proteins from spreading between brain cells—and an existing FDA-approved cancer medication targets one of those proteins.
The findings suggest that a treatment originally developed to fight melanoma, a serious form of skin cancer, could potentially help protect the brain from the progressive damage associated with Parkinson’s disease.
However, there is an important distinction: the drug has not been shown to halt Parkinson’s disease in humans. The encouraging results come from laboratory and animal research, and clinical trials would be needed to determine whether the treatment works in patients.
The original study was published in Nature Communications on May 31, 2024, and has attracted renewed attention through reporting about drug repurposing.
A New Discovery in the Fight Against Parkinson’s Disease
Parkinson’s disease is a progressive neurological disorder that affects movement, coordination, and many other functions of the nervous system.
The disease develops as certain nerve cells in the brain gradually become damaged or die.
Among the most affected are dopamine-producing neurons in a region called the substantia nigra.
Dopamine is a chemical messenger involved in controlling movement, motivation, and other essential functions.
As dopamine-producing cells deteriorate, people may begin experiencing tremors, muscle stiffness, slowed movement, walking difficulties, and problems with balance.
Although medications can help control many symptoms, researchers are still searching for treatments that reliably prevent or slow the underlying neurodegeneration.
The Johns Hopkins discovery offers a potentially important direction because it targets a biological process associated with the spread of abnormal proteins through the brain.
The Protein Behind Parkinson’s Disease Progression
One of the defining features of Parkinson’s disease is the abnormal accumulation of a protein called alpha-synuclein.
Under normal circumstances, alpha-synuclein plays a role in nerve-cell function and communication.
However, the protein can fold incorrectly, forming abnormal structures that accumulate inside neurons.
These abnormal aggregates are associated with cellular dysfunction and neurodegeneration.
Research suggests that misfolded alpha-synuclein can also spread from one neuron to another, potentially triggering additional protein misfolding in previously unaffected cells.
Scientists have therefore been investigating how these abnormal proteins enter neurons and whether blocking their movement could help protect brain tissue.
This question led researchers to two important proteins: APLP1 and LAG3.
Scientists Identify Two Proteins That Help Harmful Aggregates Enter Brain Cells
Researchers at Johns Hopkins University discovered that two proteins located on the surface of cells can work together to facilitate the uptake of abnormal alpha-synuclein.
The proteins are known as APLP1 and LAG3.
APLP1, or amyloid beta precursor-like protein 1, is involved in cellular interactions and neuronal functions.
LAG3, or lymphocyte activation gene 3, is a receptor also associated with immune regulation.
The researchers found that these proteins interact in a way that helps abnormal alpha-synuclein enter neurons.
Once inside, the harmful protein aggregates may contribute to additional cellular damage.
In experimental models, interfering with both APLP1 and LAG3 produced stronger protective effects than targeting either protein individually.
One particularly striking finding was that removing both proteins reduced the uptake of abnormal alpha-synuclein by approximately 90% under the studied experimental conditions.
The researchers also observed protection of dopamine-producing neurons and improvements in movement-related outcomes in mouse models.
These findings suggest that blocking the interaction between APLP1 and LAG3 could become a promising strategy for limiting the spread of Parkinson’s-related pathology.
The Unexpected Connection to an FDA-Approved Cancer Drug
The discovery became even more interesting when researchers considered the existing cancer treatment nivolumab/relatlimab, marketed as Opdualag.
The FDA approved this immunotherapy combination in 2022 for certain patients with advanced melanoma.
The treatment contains two monoclonal antibodies that target different immune checkpoints.
Nivolumab blocks PD-1, while relatlimab targets LAG3.
In cancer treatment, blocking these immune checkpoints helps the immune system recognize and attack cancer cells more effectively.
But LAG3 also appears to have a separate role in the movement of abnormal alpha-synuclein between brain cells.
This created an intriguing possibility.
Could a medication already designed to block LAG3 also interfere with one of the biological processes involved in Parkinson’s disease?
Researchers investigated antibodies targeting LAG3 and found that blocking this pathway could reduce the uptake and spread of harmful alpha-synuclein in experimental models.
The findings suggest that existing cancer immunotherapy research might offer valuable insights for developing neurological treatments.
What Happened When Researchers Blocked the Protein Interaction?
The research team conducted experiments involving cultured neurons and mouse models designed to reproduce certain features of Parkinson’s-related neurodegeneration.
They examined what happened when the APLP1-LAG3 interaction was disrupted.
Their findings included several encouraging observations.
Reduced uptake of toxic proteins
Blocking the interaction made it more difficult for abnormal alpha-synuclein aggregates to enter neurons.
Protection of dopamine-producing cells
Experimental animals showed reduced damage to dopamine-producing neurons under certain conditions.
Reduced spread of abnormal proteins
The findings indicated that interfering with the identified receptors could restrict the transmission of pathological alpha-synuclein.
Improved movement-related outcomes
Some experimental models demonstrated better motor outcomes when the relevant protein pathways were disrupted.
Together, these observations suggest that targeting how abnormal proteins move between brain cells could potentially help protect neurons.
Importantly, the researchers did not demonstrate that administering the approved cancer-drug combination to people stops Parkinson’s disease.
Why This Approach Is Different From Existing Parkinson’s Treatments
Most established Parkinson’s medications focus on managing symptoms caused by dopamine deficiency.
For example, levodopa helps replenish dopamine activity in the brain, often improving stiffness, tremors, and slowed movement.
Other therapies act on dopamine receptors or influence how dopamine is processed.
These treatments can substantially improve quality of life, but they generally do not stop the underlying loss of neurons.
The newly investigated strategy focuses on a different target.
Instead of primarily replacing missing dopamine, researchers hope to interfere with the spread of the abnormal proteins associated with neuronal damage.
If future therapies can successfully interrupt that process in humans, they might eventually help slow disease progression.
That would represent an important development in Parkinson’s treatment.
However, scientists still need to establish how much alpha-synuclein transmission contributes to disease progression in humans and whether blocking the APLP1-LAG3 pathway produces meaningful clinical benefits.
Could Repurposing Cancer Drugs Accelerate Medical Breakthroughs?
Developing a completely new medication can require years of laboratory research, safety testing, and clinical trials.
Drug repurposing offers an alternative approach.
Rather than beginning with an entirely new compound, scientists investigate whether a medication already approved for one condition might have therapeutic benefits for another.
Existing drugs come with substantial information about their pharmacology, manufacturing, and known side effects.
This knowledge can help researchers design further studies.
The potential advantages include lower early-stage development costs, established manufacturing processes, and previously collected human safety data.
However, approval for one disease does not establish that a drug is suitable for another.
A medication used successfully in oncology may have risks that are unacceptable for long-term treatment of a neurological condition.
In addition, scientists must determine whether a treatment reaches the relevant brain tissue in sufficient concentrations to produce its intended effects.
These questions remain particularly important for antibody-based treatments.
Is the Cancer Drug Approved for Parkinson’s Disease?
No.
As of November 2026, the nivolumab/relatlimab combination is not FDA-approved for treating Parkinson’s disease.
The research identifying the APLP1-LAG3 interaction remains preclinical.
No clinical benefit from this cancer-drug combination has been established in Parkinson’s patients.
It is also important to recognize that cancer immunotherapies can cause serious immune-related adverse reactions, including inflammation affecting organs such as the lungs, liver, intestines, heart, and endocrine glands.
These medications require specialist monitoring and should not be used experimentally outside appropriate clinical oversight.
The finding is a promising research direction, not a treatment recommendation.
What Scientists Need to Investigate Next
Before the discovery can potentially lead to a Parkinson’s treatment, researchers must answer several questions.
First, scientists need to determine whether blocking APLP1 and LAG3 can produce similar neuroprotective effects in additional experimental models.
They must also investigate whether antibodies targeting LAG3 can reach the relevant brain structures and interfere with abnormal alpha-synuclein transmission safely.
Future studies will need to examine appropriate dosing, the potential risks of prolonged immune-checkpoint inhibition, and whether more selective treatments could target neuronal LAG3 without producing excessive immune activation.
If the preclinical evidence remains encouraging, carefully designed human trials may eventually assess whether this biological approach can slow disease progression.
Until those studies are completed, claims that an FDA-approved cancer medication has already stopped Parkinson’s disease in patients are premature.
What This Discovery Means for People Living With Parkinson’s
For people affected by Parkinson’s disease, the findings represent another potentially valuable direction in neurological research.
The discovery provides scientists with a better understanding of how abnormal alpha-synuclein may move between brain cells.
It also identifies a molecular target that researchers can investigate using existing antibody technologies.
But patients should continue following evidence-based treatment plans established with their neurologists.
Current treatment options, including medication, physical activity, rehabilitation, and other supportive therapies, remain important for maintaining movement, independence, and quality of life.
The research does not justify replacing established Parkinson’s therapies with cancer medications.
Final Thoughts
The discovery that an FDA-approved cancer treatment targets a protein involved in Parkinson’s-related pathology highlights the unexpected connections that sometimes emerge between different areas of medical research.
Scientists at Johns Hopkins University identified how APLP1 and LAG3 interact to facilitate the uptake and spread of abnormal alpha-synuclein.
By disrupting this interaction, researchers were able to reduce pathological protein transmission and protect neurons in experimental models.
Because an existing melanoma treatment already targets LAG3, the findings offer an intriguing possibility for future drug development.
The major breakthrough is not that cancer medication has already cured or halted Parkinson’s disease in humans. It is that researchers have identified a potentially druggable pathway that may help prevent the spread of damaging proteins in the brain.
Whether this discovery ultimately leads to a safe and effective treatment will depend on further research and rigorous clinical testing.
For now, it offers an important scientific clue in the continuing effort to develop treatments that address the underlying causes of Parkinson’s disease rather than its symptoms alone.
Medical disclaimer: This article is for educational purposes only and should not be considered medical advice. Cancer immunotherapies are not established treatments for Parkinson’s disease. Patients should consult qualified healthcare professionals before making changes to their treatment.
